{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:49:55Z","timestamp":1792684195308,"version":"4.5.0"},"reference-count":86,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The KEYNOTE-A18 trial demonstrated that adding concurrent and adjuvant pembrolizumab to chemoradiotherapy and brachytherapy significantly improved survival in patients with newly diagnosed, locally advanced cervical cancer. However, considering the annual global incidence of 660\u202f000 cases of cervical cancer, including 13\u202f820 in the US in 2024, incorporating this regimen into the standard of care could have substantial health care economic implications for both patients and the health care system.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the cost-effectiveness of adding pembrolizumab to the first-line treatment of newly diagnosed, locally advanced cervical cancer.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This economic evaluation created a Markov model simulating 50-year outcomes to evaluate cost-effectiveness from the payer perspective for patients receiving either pembrolizumab or placebo in addition to chemoradiotherapy plus brachytherapy. Probabilities, including disease progression, survival, and treatment-related toxic effects, were derived from KEYNOTE-A18 clinical trial data in patients with newly diagnosed, locally advanced cervical cancer. Costs and health utilities were obtained from published literature; 1-way, 3-way, and probabilistic sensitivity analyses were used to assess model uncertainty. Data analyses were conducted from April to November 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Pembrolizumab.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Costs, measured in 2024 US dollars, and effectiveness, measured in quality-adjusted life-years (QALYs) were used to calculate an incremental cost-effectiveness ratio (ICER). A willingness-to-pay threshold of $100\u202f000 per QALY was chosen, below which pembrolizumab would be considered cost-effective.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n KEYNOTE-A18 enrolled 1060 patients (529 in pembrolizumab group, 531 in placebo group). The median age was 50 years. Pembrolizumab increased costs by $257\u202f000 and effectiveness by 1.40 QALYs, yielding an incremental cost-effectiveness ratio of $183\u202f400 per QALY. The addition of pembrolizumab became cost-effective if its monthly cost was decreased from $16\u202f990 to $9190 (a 45.6% reduction) or its maximum duration of 24 months was decreased to 10 months. The model was insensitive to assumptions about treatment-related toxic effects, progression-free survival, and overall survival. Probabilistic sensitivity analysis indicated that at a willingness-to-pay threshold of $100\u202f000 per QALY, the addition of pembrolizumab was cost-effective 37.3% of the time.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this economic evaluation of adding concurrent and adjuvant pembrolizumab to first-line treatment of newly diagnosed, locally advanced cervical cancer, this regimen was not cost-effective at current prices despite data demonstrating improved survival with this regimen.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.0033","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T11:30:22Z","timestamp":1741087822000},"page":"e250033","source":"Crossref","is-referenced-by-count":21,"title":["Cost-Effectiveness of Pembrolizumab With Chemoradiotherapy for Locally Advanced Cervical Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"P. Travis","family":"Courtney","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja S.","family":"Venkat","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Chen Tina","family":"Shih","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C.","family":"Raldow","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"issue":"1","key":"zoi250003r1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"zoi250003r3","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/ijc.34860","article-title":"Recent trends in cervical cancer incidence, stage at diagnosis, and mortality according to county-level income in the United States, 2000-2019.","volume":"154","author":"Amboree","year":"2024","journal-title":"Int J Cancer"},{"issue":"15","key":"zoi250003r5","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJM199904153401509","article-title":"Improved treatment for cervical cancer\u2013concurrent chemotherapy and radiotherapy.","volume":"340","author":"Thomas","year":"1999","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi250003r6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1200\/JCO.2004.07.197","article-title":"Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.","volume":"22","author":"Eifel","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi250003r7","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1470-2045(20)30753-1","article-title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.","volume":"22","author":"P\u00f6tter","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi250003r8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1001\/jamaoncol.2017.5179","article-title":"Cisplatin chemoradiotherapy vs radiotherapy in FIGO Stage IIIB squamous cell carcinoma of the uterine cervix: a randomized clinical trial.","volume":"4","author":"Shrivastava","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10167","key":"zoi250003r9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","article-title":"Cervical cancer.","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"10434","key":"zoi250003r10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"10460","key":"zoi250003r11","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"zoi250003r12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41571-024-00889-9","article-title":"Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer.","volume":"21","author":"Sidaway","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"zoi250003r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_100028","article-title":"An arm and a leg: the rising cost of cancer drugs and impact on access.","volume":"41","author":"Leighl","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"zoi250003r14","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.clinthera.2020.06.018","article-title":"Economic burden of checkpoint inhibitor immunotherapy for the treatment of non-small cell lung cancer in US clinical practice.","volume":"42","author":"Nesline","year":"2020","journal-title":"Clin Ther"},{"key":"zoi250003r15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1248867","article-title":"The future of affordable cancer immunotherapy.","volume":"14","author":"Schaft","year":"2023","journal-title":"Front Immunol"},{"issue":"10","key":"zoi250003r17","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.6004\/jnccn.2019.7305","article-title":"Financial burdens of cancer treatment: a systematic review of risk factors and outcomes.","volume":"17","author":"Smith","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"zoi250003r19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ygyno.2021.12.007","article-title":"Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.","volume":"164","author":"Shi","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"3","key":"zoi250003r20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/03007995.2023.2178081","article-title":"Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China.","volume":"39","author":"Zheng","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"zoi250003r21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1345942","article-title":"Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer.","volume":"14","author":"Lin","year":"2024","journal-title":"Front Immunol"},{"key":"zoi250003r22","doi-asserted-by":"publisher","DOI":"10.1177\/10732748231182795","article-title":"Sequential targeted therapy for advanced, metastatic, and recurrent cervical cancer: a cost-effectiveness analysis of the patient journey.","author":"Richardson","year":"2023","journal-title":"Cancer Control"},{"key":"zoi250003r24","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-024-00311-5","article-title":"Cost-effectiveness of pembrolizumab as first-line treatment in patients with persistent, recurrent, or metastatic cervical cancer in the United States.","author":"Monk","journal-title":"Oncol Ther"},{"issue":"5","key":"zoi250003r25","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1200\/JCO.22.01424","article-title":"Racial and ethnic disparities in cervical cancer incidence, survival, and mortality by histologic subtype.","volume":"41","author":"Cohen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi250003r26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.amepre.2023.04.016","article-title":"Racial and ethnic disparities in cervical cancer screening from three U.S. healthcare settings.","volume":"65","author":"Spencer","year":"2023","journal-title":"Am J Prev Med"},{"issue":"10","key":"zoi250003r27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"36","key":"zoi250003r29","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826.","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi250003r30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/jnci\/djx226","article-title":"Cost-effectiveness analysis of nivolumab for treatment of platinum-resistant recurrent or metastatic squamous cell carcinoma of the head and neck.","volume":"110","author":"Tringale","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"zoi250003r31","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.ijrobp.2020.09.045","article-title":"Cost-effectiveness analysis of stereotactic ablative radiation therapy in patients with oligometastatic cancer.","volume":"109","author":"Kumar","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"zoi250003r32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8787","article-title":"Cost-effectiveness of nivolumab-ipilimumab combination therapy for the treatment of advanced non-small cell lung cancer.","volume":"4","author":"Courtney","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi250003r33","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","article-title":"First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis.","volume":"5","author":"Wan","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"zoi250003r36","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jamaoncol.2020.1475","article-title":"Assessment of parking fees at National Cancer Institute-designated cancer treatment centers.","volume":"6","author":"Lee","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi250003r37","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/curroncol28020117","article-title":"The out-of-pocket cost burden of cancer care-a systematic literature review.","volume":"28","author":"Iragorri","year":"2021","journal-title":"Curr Oncol"},{"issue":"30","key":"zoi250003r38","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1200\/JCO.2011.35.1007","article-title":"Out-of-pocket costs for accessing adjuvant radiotherapy among Canadian women with breast cancer.","volume":"29","author":"Lauzier","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi250003r39","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1007\/s00520-013-1931-3","article-title":"Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective.","volume":"21","author":"Li","year":"2013","journal-title":"Support Care Cancer"},{"issue":"1","key":"zoi250003r43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","article-title":"A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.","volume":"7","author":"Cortellini","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"24","key":"zoi250003r44","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/jnci\/94.24.1883","article-title":"Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.","volume":"94","author":"Baker","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"zoi250003r47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020.","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"zoi250003r48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007","article-title":"Assessment of costs associated with adverse events in patients with cancer.","volume":"13","author":"Wong","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"zoi250003r49","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1080\/03007995.2019.1571297","article-title":"Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.","volume":"35","author":"Insinga","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"zoi250003r50","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jamainternmed.2019.0299","article-title":"Estimated quality of life and economic outcomes associated with 12 cervical cancer screening strategies: a cost-effectiveness analysis.","volume":"179","author":"Sawaya","year":"2019","journal-title":"JAMA Intern Med"},{"key":"zoi250003r51","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00355","article-title":"Cost effectiveness of bevacizumab plus chemotherapy for the treatment of advanced and metastatic cervical cancer in India-a model-based economic analysis.","volume":"8","author":"Gupta","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"zoi250003r52","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1477-7525-6-84","article-title":"Health state utilities for non small cell lung cancer.","volume":"6","author":"Nafees","year":"2008","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"zoi250003r53","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s11136-020-02676-2","article-title":"A systematic review of health state utility values for thyroid cancer.","volume":"30","author":"Houten","year":"2021","journal-title":"Qual Life Res"},{"key":"zoi250003r54","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1015702","article-title":"Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China.","volume":"10","author":"Li","year":"2022","journal-title":"Front Public Health"},{"issue":"9","key":"zoi250003r55","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold.","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi250003r56","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jama.2023.1792","article-title":"Cost-effectiveness thresholds used by study authors, 1990-2021.","volume":"329","author":"Neumann","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"zoi250003r57","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s40425-018-0442-7","article-title":"A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.","volume":"6","author":"Verma","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"12","key":"zoi250003r58","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi250003r59","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.medj.2024.05.001","article-title":"Immunotherapy in locally advanced cervical cancer: integrating KEYNOTE-A18 into management strategies.","volume":"5","author":"How","year":"2024","journal-title":"Med"},{"key":"zoi250003r60","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104016","article-title":"A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: the OTHERS study.","volume":"187","author":"Bogani","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"zoi250003r61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.983581","article-title":"What is the optimal duration of immune checkpoint inhibitors in malignant tumors?","volume":"13","author":"Yin","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"zoi250003r62","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer.","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol"},{"issue":"4","key":"zoi250003r65","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi250003r66","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.3390\/biomedicines11082097","article-title":"Combining radiotherapy and immunotherapy in head and neck cancer.","volume":"11","author":"Runnels","year":"2023","journal-title":"Biomedicines"},{"issue":"5","key":"zoi250003r67","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.","volume":"25","author":"Machiels","year":"2024","journal-title":"Lancet Oncol"},{"key":"zoi250003r68","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100867","article-title":"Synergizing radiotherapy and immunotherapy: current challenges and strategies for optimization.","volume":"36","author":"Rajeev-Kumar","year":"2023","journal-title":"Neoplasia"},{"issue":"3","key":"zoi250003r69","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s12325-022-02365-1","article-title":"Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab for high-risk early-stage triple-negative breast cancer in the United States.","volume":"40","author":"Huang","year":"2023","journal-title":"Adv Ther"},{"issue":"3","key":"zoi250003r70","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1001\/jamaoncol.2018.5449","article-title":"Cost-effectiveness and budgetary consequence analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non-small cell lung cancer in the context of the US health care system.","volume":"5","author":"Criss","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi250003r71","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.jval.2021.11.185","article-title":"POSA39 Cost-effectiveness analysis of nivolumab for the adjuvant treatment of patients with resected esophageal cancer (EC) or gastroesophageal junction cancer (GEJC) in Canada.","volume":"25","author":"Amadi","year":"2022","journal-title":"Value Health"},{"key":"zoi250003r73","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100625","article-title":"Cost-effectiveness of cancer drugs: comparative analysis of the United States and England.","volume":"29-30","author":"Cherla","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"2S","key":"zoi250003r75","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.jnma.2023.02.006","article-title":"Cervical cancer disparities.","volume":"115","author":"Perkins","year":"2023","journal-title":"J Natl Med Assoc"},{"issue":"3","key":"zoi250003r76","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.2985","article-title":"Mediation of racial and ethnic inequities in the diagnosis of advanced-stage cervical cancer by insurance status.","volume":"6","author":"Holt","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi250003r77","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1407","article-title":"Association of Medicaid expansion and insurance status, cancer stage, treatment and mortality among patients with cervical cancer.","volume":"4","author":"Lee","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"issue":"1","key":"zoi250003r78","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21106\/ijma.12","article-title":"Global inequalities in cervical cancer incidence and mortality are linked to deprivation, low socioeconomic status, and human development.","volume":"1","author":"Singh","year":"2012","journal-title":"Int J MCH AIDS"},{"issue":"12","key":"zoi250003r80","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.18553\/jmcp.2018.24.12.1230","article-title":"Coverage of novel therapeutic agents by Medicare prescription drug plans following FDA approval.","volume":"24","author":"Shaw","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"zoi250003r81","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1158\/1055-9965.EPI-17-0912","article-title":"Cervical cancer burden and opportunities for prevention in a safety-net healthcare system.","volume":"27","author":"Pruitt","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"50","key":"zoi250003r82","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009125","article-title":"Disparities in quality of cancer care: the role of health insurance and population demographics.","volume":"96","author":"Parikh-Patel","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"zoi250003r83","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-116-3-263","article-title":"Valuing clinical strategies early in their development.","volume":"116","author":"Welch","year":"1992","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi250003r84","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3109\/07357909709047584","article-title":"Economic analyses in clinical trials for cooperative groups: operational considerations.","volume":"15","author":"Bennett","year":"1997","journal-title":"Cancer Invest"},{"issue":"12","key":"zoi250003r85","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.jval.2020.08.2095","article-title":"Economic evaluations in National Cancer Institute-sponsored network cancer clinical trials.","volume":"23","author":"Nghiem","year":"2020","journal-title":"Value Health"},{"issue":"3","key":"zoi250003r86","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7326\/0003-4819-116-3-177","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease.","volume":"116","author":"Gulati","year":"1992","journal-title":"Ann Intern Med"},{"key":"zoi250003r2","unstructured":"World Health Organization. Cervical cancer. March 5, 2024. Accessed January 23, 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cervical-cancer"},{"key":"zoi250003r4","unstructured":"National Comprehensive Cancer Network. Cervical cancer version 3. Accessed January 23, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf"},{"key":"zoi250003r16","unstructured":"National Cancer Institute. Financial toxicity and cancer treatment (PDQ\u00ae)\u2013health professional version. September 20, 2022. Accessed January 23, 2025. https:\/\/www.cancer.gov\/about-cancer\/managing-care\/track-care-costs\/financial-toxicity-hp-pdq"},{"key":"zoi250003r18","unstructured":"Pembrolizumab (Keytruda). CADTH reimbursement recommendation: indication: treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (combined positive score = 1), as determined by a validated test, in combination with chemotherapy with or without bevacizumab. Canadian Agency for Drugs and Technologies in Health. 2022. Accessed November 22, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK601809\/"},{"key":"zoi250003r23","unstructured":"Walton? MJ, Rodgers? M, Fulbright? HA, Eastwood? AJ, Hodgson? R. Pembrolizumab plus Chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (rapid review of TA885). National Institute for Health and Care Excellence. 2023. Accessed January 23, 2025. https:\/\/pure.york.ac.uk\/portal\/en\/publications\/pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-for-p"},{"key":"zoi250003r28","unstructured":"Equator Network. Consolidated health economic evaluation reporting standards 2022 (CHEERS2022) statement: updated reporting guidance for health economic evaluations. Updated June 18, 2024. Accessed January 23, 2025. https:\/\/www.equator-network.org\/reporting-guidelines\/cheers\/"},{"key":"zoi250003r34","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results program. Published online January 18, 2024. Accessed January 23, 2025. https:\/\/seer.cancer.gov\/seerstat\/"},{"key":"zoi250003r35","unstructured":"United States Social Security Administration. Actuarial life table. Accessed January 23, 2025. https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html"},{"key":"zoi250003r40","unstructured":"Centers for Disease Control and Prevention. Medical costs and productivity losses of cancer survivors \u2014 United States, 2008\u20132011. June 13, 2014. Accessed January 23, 2025. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6323a2.htm"},{"key":"zoi250003r41","unstructured":"UpToDate. Pembrolizumab: drug information. Accessed January 23, 2025. https:\/\/www.uptodate.com\/contents\/pembrolizumab-drug-information"},{"key":"zoi250003r42","unstructured":"UpToDate. Cisplatin: Drug information. Accessed January 23, 2025. https:\/\/www.uptodate.com\/contents\/cisplatin-drug-information"},{"key":"zoi250003r45","unstructured":"Centers for Medicare & Medicaid Services. Search the physician fee schedule. Accessed January 23, 2025. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search"},{"key":"zoi250003r46","unstructured":"Consumer Price Index. CPI inflation calculator. Accessed January 23, 2025. https:\/\/data.bls.gov\/cgi-bin\/cpicalc.pl"},{"key":"zoi250003r63","unstructured":"AztraZeneca. Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based chemoradiotherapy in unresectable, Stage III non-small cell lung cancer. November 14, 2023. Accessed January 23, 2025. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/update-on-pacific-2-phase-iii-trial-for-imfinzi.html"},{"key":"zoi250003r64","unstructured":"BMS. Bristol Myers Squibb provides update on phase 3 CheckMate -73L Trial. May 10, 2024. Accessed January 23, 2025. https:\/\/news.bms.com\/news\/corporate-financial\/2024\/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-CheckMate--73L-Trial\/default.aspx"},{"key":"zoi250003r72","unstructured":"Nivolumab (Opdivo). CADTH reimbursement review: therapeutic area: esophageal or gastroesophageal junction cancer. canadian agency for drugs and technologies in health. 2022. Accessed July 1, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK596649\/"},{"key":"zoi250003r74","unstructured":"National Cancer Institute. Cancer disparities. March 21, 2024. Accessed January 23, 2025. https:\/\/www.cancer.gov\/about-cancer\/understanding\/disparities"},{"key":"zoi250003r79","unstructured":"U.S. Food and Drug Administration. FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer. January 12, 2024. Accessed January 23, 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-chemoradiotherapy-figo-2014-stage-iii-iva-cervical-cancer"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2830838\/courtney_2025_oi_250003_1740155882.2328.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T11:30:29Z","timestamp":1741087829000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2830838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.0033","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]}}}